Molecular Partners AG (XSWX:MOLN) Additional Paid-In Capital : CHF365.53 Mil(As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Molecular Partners AG Additional Paid-In Capital?

Molecular Partners AG's quarterly additional paid-in capital increased from Jun. 2023 (CHF363.38 Mil) to Sep. 2023 (CHF364.38 Mil) and increased from Sep. 2023 (CHF364.38 Mil) to Dec. 2023 (CHF365.53 Mil).

Molecular Partners AG's annual additional paid-in capital increased from Dec. 2021 (CHF355.01 Mil) to Dec. 2022 (CHF360.32 Mil) and increased from Dec. 2022 (CHF360.32 Mil) to Dec. 2023 (CHF365.53 Mil).

Molecular Partners AG Additional Paid-In Capital Historical Data

The historical data trend for Molecular Partners AG's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Molecular Partners AG Additional Paid-In Capital Chart

Molecular Partners AG Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Additional Paid-In Capital

Get a 7-Day Free Trial

182.85

299.48

355.01

360.32

365.53

Molecular Partners AG Quarterly Data
	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Additional Paid-In Capital	Get a 7-Day Free Trial															360.32	362.07	363.38	364.38	365.53

Molecular Partners AG Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Molecular Partners AG Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Molecular Partners AG's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Molecular Partners AG (XSWX:MOLN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Molecular Partners AG (XSWX:MOLN) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

MOLN:USA MLLCF:USA MOLNz:UK 6ML0:Germany

Address

Wagistrasse 14, Schlieren, Zurich, CHE, 8952

Website

https://www.molecularpartners.com

Molecular Partners AG is a clinical stage biopharmaceutical company. The company focuses on the discovery, development and prospective commercialization of a new class of biopharmaceutical products. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.